Kevin Kometer Net Worth
Track Major Insider Updates On X/TwitterLast Updated: 2 days, 7 hours ago
Kevin Kometer has an estimated net worth of at least $18.4 million*, as of Dec. 11, 2024. They own 63,207 shares of CME stock. They have sold 13,500 shares of CME stock since 2021, for an estimated $3.3 million.
Kevin Kometer $CME SEC Form 4 Insider Trading
Kevin Kometer has filed a total of 3 insider trades in $CME since 2021. Their most recent trade was a sale of 2,143 shares, made on Feb 10, 2022. Their largest trade was a sale of 6,300 shares, made on Feb 10, 2022. We estimate that they now own 63,207 shares of $CME, worth an estimated $15.1 million.
Insider Trading at $CME
There have been a total of 116 insider trades reported at $CME since 2021, with 57,436 shares purchased and 253,948 shares sold. The most active insider traders in $CME stock have been Terrence A Duffy, Hilda Harris Piell, and Timothy Francis Mccourt. The most recent trade was a sale of 750 shares reported by Elizabeth A Cook (None), made on Nov 12, 2024.
History of Insider Stock Trades by Kevin Kometer
$CME Executives and Stock Owners with Insider Trades
-
Terrence A Duffy, Chairman and CEO
-
Hilda Harris Piell, Sr MD & Chief HR Officer
-
Timothy Francis Mccourt, Sr MD Global Head Equity & FX
-
Derek Sammann, Sr MD Gl Hd Commodity & Option
-
Kevin Kometer, Sr MD Chief Information Office
-
Sean Tully, Sr MD Global Hd Financial & OT
-
Sunil Cutinho, Chief Information Officer
-
Julie Holzrichter, Sr MD Chief Operating Officer
-
Julie Winkler, Sr MD Chief Commercial Officer
-
Kathleen M Cronin, Sr MD Gen Counsel & Corp Secr
-
Ken Vroman, Chief Transformation Officer
-
Ken Vroman, Sr MD International & Optimiza
-
Lynne Fitzpatrick, Sr MD Chief Financial Officer
-
Sunil Cutinho, Sr MD & President CME Clearing
-
Suzanne Sprague, Sr MD Global Head of Clearing
*This is only based off of information found in SEC filings, and may not reflect actual net worth. There may also be inaccuracies due to privately holdings filing errors, parsing errors, accidental double-counting of shares, incorrect classification of indirectly owned shares, sales prior to dataset start date, or any other number of issues.